<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00390117</url>
  </required_header>
  <id_info>
    <org_study_id>I177</org_study_id>
    <secondary_id>CAN-NCIC-IND177</secondary_id>
    <secondary_id>CDR0000507621</secondary_id>
    <nct_id>NCT00390117</nct_id>
  </id_info>
  <brief_title>AT7519M in Treating Patients With Advanced or Metastatic Solid Tumors or Refractory Non-Hodgkin's Lymphoma</brief_title>
  <official_title>A Phase I Study of AT7519M Given Twice Weekly in Patients With Advanced Incurable Malignancy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NCIC Clinical Trials Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Canadian Cancer Trials Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: AT7519M may stop the growth of cancer cells by blocking some of the enzymes needed&#xD;
      for cell growth.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of AT7519M in treating&#xD;
      patients with advanced or metastatic solid tumors or refractory non-Hodgkin's lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the recommended phase II dose of AT7519M in patients with advanced or&#xD;
           metastatic solid tumors or refractory non-Hodgkin's lymphoma.&#xD;
&#xD;
        -  Determine the safety, tolerability, toxicity profile, and dose-limiting toxicities of&#xD;
           this drug in these patients.&#xD;
&#xD;
        -  Determine the pharmacokinetic profile of this drug in these patients.&#xD;
&#xD;
        -  Correlate the toxicity profile with pharmacokinetics of this drug in these patients.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Assess, preliminarily, the antitumor activity of this drug in these patients.&#xD;
&#xD;
      OUTLINE: This is an open-label, dose-escalation, multicenter study.&#xD;
&#xD;
      Patients receive AT7519M IV over 1-3 hours on days 1, 4, 8, and 11. Courses repeat every 21&#xD;
      days in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of AT7519M until the maximum tolerated dose&#xD;
      (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6&#xD;
      patients experience dose-limiting toxicity during course 1. Once the MTD has been determined,&#xD;
      up to 8 additional patients are treated at the MTD.&#xD;
&#xD;
      Patients undergo blood collection periodically for pharmacokinetic studies. Patients treated&#xD;
      at the MTD also undergo tumor tissue biopsies or aspirates and blood collection periodically&#xD;
      for additional pharmacodynamic and correlative biomarker studies.&#xD;
&#xD;
      After completion of study therapy, patients are followed at 4 weeks. Patients with complete&#xD;
      response, partial response, or stable disease are followed every 3 months thereafter until&#xD;
      relapse.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 22, 2006</start_date>
  <completion_date type="Actual">January 10, 2013</completion_date>
  <primary_completion_date type="Actual">March 13, 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose as assessed by NCI CTCAE v.30</measure>
    <time_frame>from time of 1st dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety, tolerability, toxicity profile, and dose-limiting toxicities as assessed by NCI CTCAE v.30</measure>
    <time_frame>from time of 1st dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic profile as measured on days 1, 2, and 4 in course 1</measure>
    <time_frame>one month</time_frame>
    <description>during cycle 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Correlation of toxicity profile with pharmacokinetics</measure>
    <time_frame>after completion of each dose level</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Preliminary antitumor activity of treatment in patients with measurable disease</measure>
    <time_frame>Every 60 days</time_frame>
    <description>after every second cycle</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response (complete and partial response) rate</measure>
    <time_frame>Every 60 days</time_frame>
    <description>after every second cycle</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response duration (median and range)</measure>
    <time_frame>after progression</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Lymphoma</condition>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <arm_group>
    <arm_group_label>CDKI AT7519</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AT7519M (1 hour IV) on days 1, 4, 8 and 11 every 5 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CDKI AT7519</intervention_name>
    <description>AT7519M (1 hour IV) on days 1, 4, 8 and 11 every 5 weeks.</description>
    <arm_group_label>CDKI AT7519</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Pharmacokinetic bioanalysis of the AT7519 plasma concentration data will be performed by BioDynamics Northhampton, U.K. The pharmacokinetic parameters for AT7519 will be determined by Astex Therapeutics as data permits.</description>
    <arm_group_label>CDKI AT7519</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed diagnosis of 1 of the following:&#xD;
&#xD;
               -  Advanced and/or metastatic solid tumor&#xD;
&#xD;
                    -  No more than 3 prior regimens for metastatic disease&#xD;
&#xD;
               -  Refractory non-Hodgkin's lymphoma&#xD;
&#xD;
          -  Clinically or radiologically documented disease&#xD;
&#xD;
               -  Patients whose only evidence of disease is tumor marker elevation are not&#xD;
                  eligible&#xD;
&#xD;
          -  No untreated brain or meningeal metastases&#xD;
&#xD;
               -  Patients with radiologic or clinical evidence of stable, treated brain metastases&#xD;
                  are eligible provided they are asymptomatic AND have no requirement for&#xD;
                  corticosteroids&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  Absolute granulocyte count ≥ 1,500/mm³&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm³&#xD;
&#xD;
          -  Creatinine ≤ 1.25 times upper limit of normal (ULN) OR creatinine clearance ≥ 50&#xD;
             mL/min&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
          -  ALT and AST ≤ 2 times ULN (5 times ULN if patient has documented liver metastases)&#xD;
&#xD;
          -  Potassium normal&#xD;
&#xD;
          -  Calcium normal&#xD;
&#xD;
          -  Creatine kinase (CK or CPK) ≤ 2 times ULN&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No pre-existing cardiovascular conditions and/or symptomatic cardiac dysfunction,&#xD;
             including any of the following:&#xD;
&#xD;
               -  Significant cardiac event (including symptomatic heart failure or angina) within&#xD;
                  the past 3 months or any cardiac disease that, in the opinion of the&#xD;
                  investigator, increases the risk for ventricular arrhythmia&#xD;
&#xD;
               -  Any history of ventricular arrhythmia, which was symptomatic or required&#xD;
                  treatment (CTC grade 3), including multifocal PVCs, bigeminy, trigeminy, or&#xD;
                  ventricular tachycardia&#xD;
&#xD;
               -  Uncontrolled hypertension&#xD;
&#xD;
               -  Previous history of QT prolongation with other medication&#xD;
&#xD;
               -  Congenital long QT syndrome&#xD;
&#xD;
               -  QT and QTc, with Bazett's correction, unmeasurable or ≥ 460 msec on screening ECG&#xD;
&#xD;
               -  LVEF &lt; 45 % by MUGA for patients with significant cardiac history (i.e.,&#xD;
                  myocardial infarction, severe hypertension, or arrhythmia) or prior doxorubicin&#xD;
                  (&gt; 450 mg/m²)&#xD;
&#xD;
          -  No active or uncontrolled infections&#xD;
&#xD;
          -  No serious illness or medical condition that would preclude study compliance&#xD;
&#xD;
          -  No peripheral neuropathy &gt; grade 1&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 21 days since prior cytotoxic chemotherapy and recovered (solid tumors)&#xD;
&#xD;
          -  At least 21 days since prior palliative radiotherapy and recovered&#xD;
&#xD;
               -  Exceptions may be made for low-dose, nonmyelosuppressive radiotherapy&#xD;
&#xD;
          -  Prior hormonal, immunologic, biologic, or signal transduction inhibitor therapy&#xD;
             allowed&#xD;
&#xD;
          -  At least 14 days since prior major surgery and recovered (no nonhealing wounds)&#xD;
&#xD;
          -  At least 4 weeks since prior steroids&#xD;
&#xD;
          -  No other concurrent medications which affect QT/QTc and cannot be discontinued&#xD;
&#xD;
          -  No other concurrent experimental drugs or anticancer therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sebastien Hotte, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Margaret and Charles Juravinski Cancer Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eric X. Chen, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Princess Margaret Hospital, Canada</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Juravinski Cancer Centre at Hamilton Health Sciences</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 5C2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. Health Network-Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <results_reference>
    <citation>Chen EX, Hotte S, Hirte H, Siu LL, Lyons J, Squires M, Lovell S, Turner S, McIntosh L, Seymour L. A Phase I study of cyclin-dependent kinase inhibitor, AT7519, in patients with advanced cancer: NCIC Clinical Trials Group IND 177. Br J Cancer. 2014 Dec 9;111(12):2262-7. doi: 10.1038/bjc.2014.565. Epub 2014 Nov 13.</citation>
    <PMID>25393368</PMID>
  </results_reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>October 18, 2006</study_first_submitted>
  <study_first_submitted_qc>October 18, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 2006</study_first_posted>
  <last_update_submitted>April 6, 2020</last_update_submitted>
  <last_update_submitted_qc>April 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <keyword>recurrent adult Burkitt lymphoma</keyword>
  <keyword>recurrent adult diffuse large cell lymphoma</keyword>
  <keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
  <keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
  <keyword>recurrent adult lymphoblastic lymphoma</keyword>
  <keyword>recurrent adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>recurrent grade 1 follicular lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <keyword>recurrent mantle cell lymphoma</keyword>
  <keyword>recurrent marginal zone lymphoma</keyword>
  <keyword>recurrent small lymphocytic lymphoma</keyword>
  <keyword>Waldenstrom macroglobulinemia</keyword>
  <keyword>recurrent adult grade III lymphomatoid granulomatosis</keyword>
  <keyword>adult nasal type extranodal NK/T-cell lymphoma</keyword>
  <keyword>nodal marginal zone B-cell lymphoma</keyword>
  <keyword>splenic marginal zone lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

